Beeologics

AviServe aims to provide an accurate, contemporary, responsive and science based resource laboratory and consulting service for use by the poultry and allied industries. The company aims to assist clients with the recognition and control of conventional and complex diseases that affect the profitability of the poultry, biologics, diagnostics and animal pharmaceuticals industries. Per the company, they have the ability to develop disease diagnostics and control strategies that can be individualized on a company or geographical basis.

ncorporated in November 2005, with an asset value of about 10 million USD, Stemgen's labs are located in University of Bicocca - Milan with a currrent staff of 10 people including management and research staff. The Company has recently filed a PCT procedure covering the use of new potent anti-tumour molecules effective against glioblastoma multiforme (GBM). Each year up to 30.000 new cases of GBM are diagnosed in the world's seven largest healthcare markets and this specific market is still characterised by a high level of unmet therapeutic needs, despite the approval of several new products in the USA and Europe in recent years. The company's primary goal is to offer a therapy that will succed in covering this need. Once the company's new molecules are developed, licensing and strategic alliances policy will enable Stemgen to enter the GBM-therapy market.

Oncology Research Therapeutics, Inc. is dedicated to providing and discovering cancer diagnostics that improve the lives of patients suffering from a wide array of cancers. They also provide R&D services that improve drug development for the Biotech and Pharmaceutical industries.

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

FirstString Research is a biopharmaceutical company focused on the development of drugs using its proprietary alpha-connexin carboxyl-terminus 1 (aCT1) peptide technology. The company's main offerings include treatments designed to revolutionize the body's response to injury, with applications in dermatology, ophthalmology, and pulmonology. It is based in Mount Pleasant, South Carolina.

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.